MBI Med Biogene Inc

Precision Therapeutics, Inc. and Med BioGene Inc. (TSX VENTURE:MBI) today
announced that Precision Therapeutics has successfully completed their
previously announced clinical studies to validate the use of LungExpress Dx(TM)
with tissue preserved by RNAlater(R), a molecular fixative.


RNAlater eliminates the need to flash-freeze specimens and to keep specimens
frozen throughout storage and transport, a process that can be cumbersome and
costly. It also eliminates the need for preserving tissue in formalin, which is
known to cross-link and degrade the nucleic acids rendering them less suitable
for specific downstream molecular applications.


The clinical studies were conducted using patient specimens prospectively
accrued by Precision from a consortium of medical centers in the United States.


Precision expects to commence commercialization of LungExpress Dx in its
CLIA-certified laboratory by mid-2013. In advance of commercialization,
Precision has established an advisory board comprised of world leaders in lung
cancer research and treatment from the United States, Canada, France and Italy.


"Precision's efforts in commercializing this important test underscores our
ongoing commitment to improving the outcomes of cancer patients by providing
personalized medicine solutions that aim to increase quality of life and cancer
survival rates," said Sean McDonald, Precision's President and Chief Executive
Officer. "The successful completion of our clinical studies provides further
evidence of the robustness of our test and we are moving closer to providing
patients and doctors with a tool to address a critical unmet need."


Erinn Broshko, Executive Chairman of Med BioGene, commented: "We are very
pleased with the progress made by Precision and are looking forward to our
clinically valuable test being available to lung cancer patients. The commercial
success of a molecular diagnostic test depends, in large measure, upon the
extent of its integration into current pathological processes. The use of
LungExpress Dx with RNAlater will allow pathologists to avoid the logistics
involved with using flash-frozen tumor specimens and, instead, to handle and
ship specimens at room temperature, thereby simplifying the process
significantly. We believe that this will materially enhance the commercial
prospects of our test."


About LungExpress Dx

LungExpress Dx is a proprietary gene expression-based test to improve upon
staging for identifying those patients with early-stage non-small-cell lung
cancer (NSCLC) who, following surgical removal of their tumor, are at higher and
lower risks of mortality. In an initial study of patient specimens from the
National Cancer Institute of Canada Clinical Trials Group JBR.10 trial,
published in the Journal of Clinical Oncology, patients classified by
LungExpress Dx as higher risk benefited from adjuvant chemotherapy, and those
classified as lower risk did not benefit and may have experienced a detrimental
effect from adjuvant chemotherapy. LungExpress Dx was subsequently validated in
predicting patient mortality in four independent studies involving data from
tumor specimens totaling 676 untreated early-stage NSCLC patients. LungExpress
Dx is expected to provide better-informed and personalized treatment decisions
to assist in the selection of patients for adjuvant chemotherapy.


On April 15, 2011, Precision and Med BioGene closed their commercialization,
license and research reimbursement agreement. The agreement provides to
Precision exclusive global rights to develop and commercialize LungExpress Dx.


About Precision Therapeutics

Precision, a leading life science company based in Pittsburgh, Pennsylvania, is
dedicated to improving the outcomes of cancer patients by providing personalized
medicine solutions that aim to increase quality of life and cancer survival
rates. Precision offers a portfolio of products developed to help guide
physicians and patients with difficult clinical decisions throughout the cancer
care continuum. For more information, please visit
www.precisiontherapeutics.com.


About Med BioGene

Med BioGene is a life science company based in Vancouver, British Columbia that
is currently focused on managing the license and rights to LungExpress Dx. Med
BioGene's common shares are listed for trading on the TSX Venture Exchange. For
more information, please visit www.medbiogene.com.


Certain statements in this press release contain forward-looking statements and
information ("forward-looking statements") under applicable United States and
Canadian securities legislation. Words such as "anticipates", "believes",
"estimates", "expects", "intends", "may", "plans", "projects", "will", "would"
and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words.
Forward-looking statements include, but are not limited to, that with respect to
the timing, completion and/or results of clinical trials or studies, the timing
for commercialization of any products, future profits, future product revenues,
future shareholder value, future operations and plans, the completion and use of
proceeds from transactions or financings and the prospects for negotiating
partnerships or collaborations and their timing. These forward-looking
statements are only a prediction based upon the party's current expectations,
and actual events or results may differ materially. A party may not actually
achieve the plans, intentions or expectations disclosed in its forward-looking
statements. Forward-looking statements are subject to known and unknown risks
and uncertainties and are based on uncertain assumptions that could cause a
party's actual results and the timing of events to differ materially from those
anticipated in such forward-looking information. You are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date of this press release. A party's forward-looking statements do not reflect
the potential impact of any future partnerships, collaborations, acquisitions,
mergers, dispositions, joint ventures or investments that that party may make.
All forward-looking statements are qualified in their entirety by this
cautionary statement and a party undertakes no obligation to revise or update
any forward-looking statements as a result of new information, future events or
otherwise after the date of this press release, other than as required by
applicable law. Certain information included in this press release in respect of
Precision and its scientific, clinical and/ or commercialization efforts have
been provided to Med BioGene by Precision. Med BioGene may not have been able to
confirm the accuracy of such information and you should not place undue reliance
on any such information, including any information regarding Precision that
would constitute forward-looking information. A redacted copy of the
commercialization agreement, as amended, between Precision and Med BioGene may
be found at www.sedar.com. Each trademark, trade name or service mark of any
entity appearing in this news release belongs to its holder.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Med BioGene Inc.
Erinn B. Broshko
Executive Chairman
(800) 641-3593
ebroshko@medbiogene.com
www.medbiogene.com


Precision Therapeutics, Inc.
Pam Ranallo
Media Contact
(412) 432-1500 ext. 1502
pranallo@ptilabs.com
www.precisiontherapeutics.com

Med Biogene (TSXV:MBI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024

Med Biogene (TSXV:MBI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024